Dental Pulp Stem Cell Supernatant for Refractive Error Correction

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

There is a growing need for effective agents to improve ocular symptoms such as myopia, astigmatism, presbyopia, eye fatigue, and blurred vision, which are increasingly prevalent due to factors like prolonged screen time and aging.

Innovation Solution

A culture supernatant of dental pulp-derived stem cells or immortalized stem cells thereof is used as a composition to improve ocular symptoms. This supernatant contains bioactive substances that can enhance visual function and alleviate symptoms of myopia, astigmatism, presbyopia, eye fatigue, and blurred vision.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional culture supernatants from immortalized stem cells or bone marrow mesenchymal stem cells are used, then certain ocular symptoms (such as pollinosis or cataract) may be improved, but improvement in refractive errors (myopia, astigmatism, presbyopia) and eye fatigue has not been achieved or examined

Engineering Contradiction:
Improveeffectiveness for refractive errors and eye fatigueVSAvoidapplicability to multiple ocular symptoms
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the source parameter of stem cells from immortalized cells or bone marrow mesenchymal stem cells to dental pulp-derived stem cells. This parameter change in cell origin results in a culture supernatant with different bioactive substance composition that is specifically effective for refractive errors (myopia, astigmatism, presbyopia) and eye fatigue, while maintaining effectiveness for other ocular symptoms.

Inventive Principle:
Principle #35Parameter changes

2Manufacturing precision

If PTL 3's bone marrow mesenchymal stem cell culture supernatant is used, then lens tissue compressibility and recovery ability is improved, but actual eyesight improvement in human patients with presbyopia has not been examined

Engineering Contradiction:
Improvelens tissue elasticityVSAvoideyesight improvement measurement
Core Design Contradiction:
Manufacturing precisionVSMeasurement precision

Solution Approach 1:

The patent uses dental pulp-derived stem cells that can self-differentiate into ocular tissue-compatible cells. The culture supernatant contains bioactive substances that directly act on ocular tissues including the lens, promoting natural regeneration and improvement of both lens elasticity and eyesight without requiring external intervention or conversion to other cell types.

Inventive Principle:
Principle #25Self-service

Data Source

PatentEP4335447B1Culture supernatant of dental pulp-derived stem cells for improving myopia, astigmatism, presbyopia, eye fatigue or blurred vision
Publication Date: 2025.06.18 PANERGY CO LTD
  • EP4335447B1 patent drawingFigure 1
  • EP4335447B1 patent drawingFigure 2
  • EP4335447B1 patent drawingFigure 3~4

AI summary

An ocular symptom-improving agent which is a composition containing a culture supernatant of dental pulp-derived stem cells or immortalized stem cells thereof and which is used for improving a symptom of myopia, astigmatism, presbyopia, eye fatigue or blurred vision is a novel ocular symptom-improving agent; a method for improving an ocular symptom.